FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.97
+1.84%Aug 25, 2026, 07:55 UTC
Bank of America Corp DE increased its stake in 4D Molecular Therapeutics, Inc. by 17.0% during the first quarter, acquiring an additional 141,582 shares, according to a recent SEC filing.
Source:Aug 14, 2026, 14:00 UTC
4D Molecular Therapeutics plans to initiate a Phase 3 trial for 4D-150 in diabetic macular edema in Q3 2026.
Source:Aug 13, 2026, 23:06 UTC
4D Molecular Therapeutics, Inc. reported a Q2 2026 loss of $1.04 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.98 per share a year ago.
Source:Aug 13, 2026, 20:05 UTC
4D Molecular Therapeutics entered into a strategic credit facility agreement with Hercules Capital for up to $200 million, with an initial draw of $20 million.
Jun 29, 2026, 12:00 UTC
4D Molecular Therapeutics completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 in wet AMD.
Source:Jun 29, 2026, 12:00 UTC
4D Molecular Therapeutics entered into a strategic credit facility agreement with Hercules Capital for up to $200 million.
Source: